TY - JOUR A1 - de Zeeuw, Dick A1 - Akizawa, Tadao A1 - Agarwal, Rajiv A1 - Audhya, Paul A1 - Bakris, George L. A1 - Chin, Melanie A1 - Krauth, Melissa A1 - Lambers Heerspink, Hiddo J. A1 - Meyer, Colin J. A1 - McMurray, John J. A1 - Parving, Hans-Henrik A1 - Pergola, Pablo E. A1 - Remuzzi, Giuseppe A1 - Toto, Robert D. A1 - Vaziri, Nosratola D. A1 - Wanner, Christoph A1 - Warnock, David G. A1 - Wittes, Janet A1 - Chertow, Glenn M. T1 - Rationale and Trial Design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: The Occurrence of Renal Events (BEACON) JF - American Journal of Nephrology N2 - Background: Chronic kidney disease (CKD) associated with type 2 diabetes mellitus constitutes a global epidemic complicated by considerable renal and cardiovascular morbidity and mortality, despite the provision of inhibitors of the renin-angiotensin-aldosterone system (RAAS). Bardoxolone methyl, a synthetic triterpenoid that reduces oxidative stress and inflammation through Nrf2 activation and inhibition of NF-κB was previously shown to increase estimated glomerular filtration rate (eGFR) in patients with CKD associated with type 2 diabetes mellitus. To date, no antioxidant or anti-inflammatory therapy has proved successful at slowing the progression of CKD. Methods: Herein, we describe the design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON) trial, a multinational, multicenter, double-blind, randomized, placebo-controlled Phase 3 trial designed to determine whether long-term administration of bardoxolone methyl (on a background of standard therapy, including RAAS inhibitors) safely reduces renal and cardiac morbidity and mortality. Results: The primary composite endpoint is time-to-first occurrence of either end-stage renal disease or cardiovascular death. Secondary endpoints include the change in eGFR and time to occurrence of cardiovascular events. Conclusion: BEACON will be the first event-driven trial to evaluate the effect of an oral antioxidant and anti-inflammatory drug in advanced CKD. KW - clinical trial KW - diabetes mellitus KW - glomerular filtration rate KW - trial design KW - bardoxolone methyl KW - Nrf2 KW - end-stage renal disease KW - cardiovascular death KW - chronic kidney disease Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-196832 SN - 0250-8095 SN - 1421-9670 N1 - This publication is with permission of the rights owner freely accessible due to an Alliance licence and a national licence (funded by the DFG, German Research Foundation) respectively. VL - 37 IS - 3 ER - TY - JOUR A1 - Kühn, Heike A1 - Schön, Franz A1 - Edelmann, Karola A1 - Brill, Stefan A1 - Müller, Joachim T1 - The Development of Lateralization Abilities in Children with Bilateral Cochlear Implants JF - ORL N2 - Objectives: The purpose of this study was to investigate the development of lateralization skills in children who received bilateral cochlear implants (CIs) in sequential operations. Methods: The lateralization skills of 9 children with a mean age of 4.1 years at the first surgery and 5.5 years at the second surgery were assessed at 3 time intervals. Children were assessed with a 3-loudspeaker setup (front, left and right) at 0.9 years (interval I) and 1.6 years (interval II) after the second implantation, and after 5.3 years of bilateral implant use (interval III) with a 9-loudspeaker setup in the frontal horizontal plane between -90° and 90° azimuth. Results: With bilateral implants, a significant decrease in lateralization error was noted between test interval I (45.0°) and II (23.3°), with a subsequent significant decrease at test interval III (4.7°). Unilateral performance with the CI did not improve significantly between the first 2 intervals; however, there was a bias of responses towards the unilateral side by test interval III. Conclusions: The lateralization abilities of children with bilateral CIs develop in a relatively short period of time (1-2 years) after the second implant. Children appear to be able to acquire binaural skills after bilateral cochlear implantation. KW - localization KW - bilateral cochlear implant KW - children KW - MED-EL cochlear implant KW - lateralization Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-196375 SN - 0301-1569 SN - 1423-0275 N1 - This publication is with permission of the rights owner freely accessible due to an Alliance licence and a national licence (funded by the DFG, German Research Foundation) respectively. VL - 75 IS - 2 ER - TY - JOUR A1 - Heinrich, T. A1 - Nanda, I. A1 - Rehn, M. A1 - Zollner, U. A1 - Frieauff, E. A1 - Wirbelauer, J. A1 - Grimm, T. A1 - Schmid, M. T1 - Live-Born Trisomy 22: Patient Report and Review JF - Molecular Syndromology N2 - Trisomy 22 is a common trisomy in spontaneous abortions. In contrast, live-born trisomy 22 is rarely seen due to severe organ malformations associated with this condition. Here, we report on a male infant with complete, non-mosaic trisomy 22 born at 35 + 5 weeks via caesarean section. Peripheral blood lymphocytes and fibroblasts showed an additional chromosome 22 in all metaphases analyzed (47,XY,+22). In addition, array CGH confirmed complete trisomy 22. The patient’s clinical features included dolichocephalus, hypertelorism, flattened nasal bridge, dysplastic ears with preauricular sinuses and tags, medial cleft palate, anal atresia, and coronary hypospadias with scrotum bipartitum. Essential treatment was implemented in close coordination with the parents. The child died 29 days after birth due to respiratory insufficiency and deterioration of renal function. Our patient’s history complements other reports illustrating that children with complete trisomy 22 may survive until birth and beyond. KW - chromosomal abnormality KW - live-born KW - non-mosaic KW - trisomy 22 Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-196535 SN - 1661-8769 SN - 1661-8777 N1 - This publication is with permission of the rights owner freely accessible due to an Alliance licence and a national licence (funded by the DFG, German Research Foundation) respectively. VL - 3 IS - 6 ER - TY - JOUR A1 - Matthies, Cordula A1 - Brill, Stefan A1 - Kaga, Kimitaka A1 - Morita, Akio A1 - Kumakawa, Kozo A1 - Skarzynski, Henryk A1 - Claassen, Andre A1 - Hui, Yau A1 - Chiong, Charlotte A1 - Müller, Joachim A1 - Behr, Robert T1 - Auditory Brainstem Implantation Improves Speech Recognition in Neurofibromatosis Type II Patients JF - ORL N2 - This prospective study aimed to determine speech understanding in neurofibromatosis type II (NF2) patients following implantation of a MED-EL COMBI 40+ auditory brainstem implant (ABI). Patients (n = 32) were enrolled postsurgically. Nonauditory side effects were evaluated at fitting and audiological performance was determined using the Sound Effects Recognition Test (SERT), Monosyllable-Trochee-Polysyllable (MTP) test and open-set sentence tests. Subjective benefits were determined by questionnaire. ABI activation was documented in 27 patients, 2 patients were too ill for testing and 3 patients were without any auditory perception. SERT and MTP outcomes under auditory-only conditions improved significantly between first fitting and 12-month follow-up. Open-set sentence recognition improved from 5% at first fitting to 37% after 12 months. The number of active electrodes had no significant effect on performance. All questionnaire respondents were ‘satisfied' to ‘very satisfied' with their ABI. An ABI is an effective treatment option in NF2 patients with the potential to provide open-set speech recognition and subjective benefits. To our knowledge, the data presented herein is exceptional in terms of the open-set speech perception achieved in NF2 patients. KW - acoustic neuroma KW - auditory brainstem implant KW - nonauditory side effects KW - open-set sentence recognition KW - subjective benefits KW - vestibular schwannoma Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-196383 SN - 0301-1569 SN - 1423-0275 N1 - This publication is with permission of the rights owner freely accessible due to an Alliance licence and a national licence (funded by the DFG, German Research Foundation) respectively. VL - 75 IS - 5 ER - TY - JOUR A1 - Weber, Christoph A1 - Gräf, Stephan T1 - Eine halb so schlimme Täuschung JF - JURA - Juristische Ausbildung N2 - Kein Abstract verfügbar. KW - Examensklausur Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-195484 SN - 1612-7021 SN - 0170-1452 N1 - Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich. VL - 36 IS - 1 ER - TY - JOUR A1 - Pfister, Roland A1 - Schwarz, Katharina A. A1 - Janczyk, Markus A1 - Dale, Rick A1 - Freeman, Jonathan B. T1 - Good things peak in pairs: a note on the bimodality coefficient JF - Frontiers in Psychology N2 - A commentary on Assessing bimodality to detect the presence of a dual cognitive process by Freeman, J. B., and Dale, R. (2013). Behav. Res. Methods 45, 83–97. doi: 10.3758/s13428-012-0225-x KW - distribution analysis KW - bimodality Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-190413 SN - 1664-1078 VL - 4 ER - TY - JOUR A1 - Foerster, Anna A1 - Pfister, Roland A1 - Schmidts, Constantin A1 - Dignath, David A1 - Kunde, Wilfried T1 - Honesty saves time (and justifications) JF - Frontiers in Psychology N2 - A commentary on Honesty requires time (and lack of justifications) by Shalvi, S., Eldar, O., and Bereby-Meyer, Y. (2012). Psychol. Sci. 23, 1264–1270. doi: 10.1177/0956797612443835 KW - honesty Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-190451 SN - 1664-1078 VL - 4 ER - TY - JOUR A1 - Meule, Adrian A1 - Vögele, Claus T1 - The psychology of eating JF - Frontiers in Psychology N2 - No abstract available. Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-190460 SN - 1664-1078 VL - 4 ER - TY - JOUR A1 - Meule, Adrian T1 - Impulsivity and overeating: a closer look at the subscales of the Barratt Impulsiveness Scale JF - Frontiers in Psychology N2 - No abstract available. KW - Impulsivity KW - Overeating Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-190497 SN - 1664-1078 VL - 4 ER - TY - JOUR A1 - Kress, Michaela A1 - Hüttenhofer, Alexander A1 - Landry, Marc A1 - Kuner, Rohini A1 - Favereaux, Alexandre A1 - Greenberg, David A1 - Bednarik, Josef A1 - Heppenstall, Paul A1 - Kronenberg, Florian A1 - Malcangio, Marzia A1 - Rittner, Heike A1 - Üçeyler, Nurcan A1 - Trajanoski, Zlatko A1 - Mouritzen, Peter A1 - Birklein, Frank A1 - Sommer, Claudia A1 - Soreq, Hermona T1 - microRNAs in nociceptive circuits as predictors of future clinical applications JF - Frontiers in Molecular Neuroscience N2 - Neuro-immune alterations in the peripheral and central nervous system play a role in the pathophysiology of chronic pain, and non-coding RNAs – and microRNAs (miRNAs) in particular – regulate both immune and neuronal processes. Specifically, miRNAs control macromolecular complexes in neurons, glia and immune cells and regulate signals used for neuro-immune communication in the pain pathway. Therefore, miRNAs may be hypothesized as critically important master switches modulating chronic pain. In particular, understanding the concerted function of miRNA in the regulation of nociception and endogenous analgesia and defining the importance of miRNAs in the circuitries and cognitive, emotional and behavioral components involved in pain is expected to shed new light on the enigmatic pathophysiology of neuropathic pain, migraine and complex regional pain syndrome. Specific miRNAs may evolve as new druggable molecular targets for pain prevention and relief. Furthermore, predisposing miRNA expression patterns and inter-individual variations and polymorphisms in miRNAs and/or their binding sites may serve as biomarkers for pain and help to predict individual risks for certain types of pain and responsiveness to analgesic drugs. miRNA-based diagnostics are expected to develop into hands-on tools that allow better patient stratification, improved mechanism-based treatment, and targeted prevention strategies for high risk individuals. KW - chronic pain KW - biomarker KW - polymorphism KW - miRNA-based diagnostics KW - miRNA expression patterns KW - miRNA polymorphisms KW - antagomir KW - miRNA-based analgesic Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-154597 VL - 6 IS - 33 ER -